Cargando…
Appetite and food intake results from phase I studies of anamorelin
BACKGROUND: Loss of appetite and body weight are potentially devastating, highly prevalent cancer complications. The ghrelin receptor is a mediator of appetite and metabolism, and anamorelin is a novel, orally administered ghrelin receptor agonist. Effects on appetite and food intake may influence b...
Autores principales: | Blum, Robert A., Mair, Stuart, Duus, Elizabeth M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818453/ https://www.ncbi.nlm.nih.gov/pubmed/31074178 http://dx.doi.org/10.1002/jcsm.12439 |
Ejemplares similares
-
Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study
por: Garcia, Jose M, et al.
Publicado: (2014) -
Oncology Update: Anamorelin
por: Prommer, Eric
Publicado: (2017) -
Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile
por: Pietra, Claudio, et al.
Publicado: (2014) -
Refractory Monomorphic Ventricular Tachycardia Induced by Anamorelin
por: Sakagami, Hiroaki, et al.
Publicado: (2022) -
The Effects of Oxytocin on Appetite Regulation, Food Intake and Metabolism in Humans
por: Kerem, Liya, et al.
Publicado: (2021)